86 related articles for article (PubMed ID: 24427833)
21. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
[TBL] [Abstract][Full Text] [Related]
22. Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib.
Nakatomi K; Soda H; Kitazaki T; Nakano H; Uchida K; Urabe S; Nakamura Y; Hayashi T; Tsukamoto K; Kohno S
Lung Cancer; 2006 May; 52(2):253-5. PubMed ID: 16554105
[TBL] [Abstract][Full Text] [Related]
23. The TAILOR study: to agree or to disagree?
Moro-Sibilot D; Perol D; Chabaud S; Cadranel J; Audigier Valette C; Perol M
Lung Cancer; 2014 Jun; 84(3):315-6. PubMed ID: 24751106
[No Abstract] [Full Text] [Related]
24. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
[TBL] [Abstract][Full Text] [Related]
25. Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.
Kim HS; Park K; Jun HJ; Yi SY; Lee J; Ahn JS; Park YH; Kim S; Lee S; Ahn MJ
Oncology; 2009; 76(4):239-46. PubMed ID: 19246948
[TBL] [Abstract][Full Text] [Related]
26. [Gefitinib as targeted treatment for non-small-cell lung cancer].
Knuuttila A; Karjalainen EM; Rouhos A; Mali P
Duodecim; 2005; 121(3):267-72. PubMed ID: 15787284
[No Abstract] [Full Text] [Related]
27. Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
Popat S; Barbachano Y; Ashley S; Norton A; O'Brien M
Lung Cancer; 2008 Feb; 59(2):227-31. PubMed ID: 17920156
[TBL] [Abstract][Full Text] [Related]
28. First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.
Lie CH; Chang HC; Chao TY; Chung YH; Wang JL; Wang CC; Lin MC
Clin Lung Cancer; 2011 Mar; 12(2):116-24. PubMed ID: 21550558
[TBL] [Abstract][Full Text] [Related]
29. [Non-small cell lung cancer: 2) Epidermal growth factor receptor inhibitor and severe adverse phenomena].
Kudo S; Yoshimura A; Genma A
Nihon Naika Gakkai Zasshi; 2003 Jul; 92(7):1291-5. PubMed ID: 12924276
[No Abstract] [Full Text] [Related]
30. Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Qi WX; Tang LN; He AN; Yao Y; Shen Z
Respir Med; 2013 Aug; 107(8):1280-3. PubMed ID: 23810268
[TBL] [Abstract][Full Text] [Related]
31. Erlotinib-associated dermatological toxicity.
Mumoli N; Cei M; Vitale J
QJM; 2013 Apr; 106(4):363-4. PubMed ID: 22927541
[No Abstract] [Full Text] [Related]
32. Three-year survival in metastatic non-small cell lung cancer treated with gefitinib.
Costa DB; Schumer ST
Lung Cancer; 2006 Jul; 53(1):123-4. PubMed ID: 16723171
[No Abstract] [Full Text] [Related]
33. [Gefitinib therapy in non-small-cell lung cancer].
Jänne PA
Duodecim; 2005; 121(3):249-51. PubMed ID: 15787283
[No Abstract] [Full Text] [Related]
34. Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?
Okamoto I; Suga M
Intern Med; 2003 Oct; 42(10):926-7. PubMed ID: 14606701
[No Abstract] [Full Text] [Related]
35. Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?: Commentary re: P. M. LoRusso, Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin. Cancer Res., 9: 2040-2048, 2003.
Patrick-Miller LJ
Clin Cancer Res; 2003 Jun; 9(6):1990-4. PubMed ID: 12796360
[No Abstract] [Full Text] [Related]
36. Third-line chemotherapy for advanced non-small-cell lung cancer--is there enough evidence to support its use?
Yang CH
J Chin Med Assoc; 2005 Apr; 68(4):160-1. PubMed ID: 15850063
[No Abstract] [Full Text] [Related]
37. Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib.
Ho C; Davis J; Anderson F; Bebb G; Murray N
J Clin Oncol; 2005 Nov; 23(33):8531-3. PubMed ID: 16293881
[No Abstract] [Full Text] [Related]
38. [Transient liver injury caused by gefitinib].
Yoshimoto A; Kasahara K; Kimura H; Kita T; Fujimura M; Nakao S
Nihon Kokyuki Gakkai Zasshi; 2004 Jan; 42(1):56-61. PubMed ID: 14768365
[TBL] [Abstract][Full Text] [Related]
39. I am no one. No one is perfect...Therefore I am perfect.
Tassinari D; Lazzari-Agli L; Tombesi P; Sartori S
J Clin Oncol; 2009 Oct; 27(28):e128-9; author reply e130-1. PubMed ID: 19720902
[No Abstract] [Full Text] [Related]
40. What went wrong with Iressa?
Burton A
Lancet Oncol; 2002 Dec; 3(12):708. PubMed ID: 12473493
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
